Poxel S.A(7PO)

Description: Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

---

Keywords: Biopharmaceutical Disease Diabetes Hepatitis Hepatitis B Liver Disease Metabolic Disease Metabolic Disorders Non Alcoholic Fatty Liver Disease Steatohepatitis Adenosine Endocrine Diseases Metabolic Dysfunction–Associated Steatotic Liver Disease Obeticholic Acid Treatment Of Hepatitis B Draft:Viking Therapeutics Mitochondrion Mitochondrial Disease Mitochondrial Dysfunction Chronic Metabolic Diseases Imeglimin Pxl065 Pxl770

---

Home Page: www.poxelpharma.com

Immeuble Le Sunway
Lyon, 69007
France
Phone: 33 1 44 71 94 94

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)